Cardiovascular Disease Cohort in Guangdong Province

Sponsor
Min Xia (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03351907
Collaborator
(none)
5,000
1
158
31.7

Study Details

Study Description

Brief Summary

Patients with cardiovascular diseases from Guangdong province will be recruited and followed up for at least 4 years to evaluate the risk factors for cardiovascular-related mortality and disability. Physical examination, questionnaire survey and biological sample collection will be conducted at baseline and the incidence of all-cause and cardiovascular mortality will be investigated during follow-up.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    5,000 patients (30-85 years old) with primary hypertension, coronary heart disease, heart failure or peripheral vascular disease and who have been living in Guangdong province for more than 5 years will be recruited. All participants will be prospectively followed up for the incidence of all-cause and cardiovascular mortality. Information about socio-demographic, diet, lifestyle, psychological status, medical history and current medication will be collected by questionnaires. Physical examinations including height, weight, waist and hip circumferences, blood pressure, fat mass and vital capacity will be conducted.Besides, blood, urine and fecal samples will be collected for further analysis. The associations between diet and lifestyle and risks for cardiovascular disease will be evaluated.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    5000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Prospective Cohort Study of Cardiovascular Disease in Guangdong Province
    Actual Study Start Date :
    Nov 1, 2017
    Anticipated Primary Completion Date :
    Dec 31, 2030
    Anticipated Study Completion Date :
    Dec 31, 2030

    Outcome Measures

    Primary Outcome Measures

    1. All-Cause Mortality [4 years]

      All-cause mortality was confrmed through a combination of hospital medical records, telephone contacts with patients or family members, and death registration at the Guangdong Provincial Center for Disease Control and Prevention.

    Secondary Outcome Measures

    1. Cardiovascular Mortality [4 years]

      Cardiovascular mortality was defned as death attributable to an ischemic cardiovascular cause (including fatal MI, stroke, and peripheral arterial disease) or sudden death due to an unknown but presumed cardiovascular cause in high-risk patients.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Cardiovascular disease patients (30-85 years old) who have been living in Guangdong province for more than 5 years.

    • Patients have been diagnosed with primary hypertension, coronary heart disease, heart failure or peripheral vascular disease, etc.

    Exclusion Criteria:
    • Patients with cardiogenic (acute pericarditis, rheumatic coronary arteritis, hypertrophic cardiomyopathy, etc.) Or non-cardiogenic chest pain.

    • any subject who suffer from malignant tumors, infectious diseases, advanced liver disease, major disability and cannot participate in the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sun Yat-Sen University Guangzhou Guangdong China 510080

    Sponsors and Collaborators

    • Min Xia

    Investigators

    • Principal Investigator: Min Xia, School of Public Health,Nutrition and Food Hygiene,Sun Yat-sen University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Min Xia, Professer, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT03351907
    Other Study ID Numbers:
    • 2017XXG1120
    First Posted:
    Nov 24, 2017
    Last Update Posted:
    May 5, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 5, 2022